UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000479
Receipt number R000000579
Scientific Title An investigational study of chemoradiosensitivity prediction with genetic profiling of esophageal biopsy for squamous cell carcinoma of the esophagus
Date of disclosure of the study information 2007/02/01
Last modified on 2009/09/02 15:09:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

An investigational study of chemoradiosensitivity prediction with genetic profiling of esophageal biopsy for squamous cell carcinoma of the esophagus

Acronym

Prediction of chemoradiosensitivity with genetic profiling for esophageal squamous cell carcinoma

Scientific Title

An investigational study of chemoradiosensitivity prediction with genetic profiling of esophageal biopsy for squamous cell carcinoma of the esophagus

Scientific Title:Acronym

Prediction of chemoradiosensitivity with genetic profiling for esophageal squamous cell carcinoma

Region

Japan


Condition

Condition

Esophageal cancer

Classification by specialty

Gastroenterology Gastrointestinal surgery Radiology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To search for chemoradiosensitivity related genes using a pretreatment biopsy sample and to establish an algorithm for prediction of chemoradiosensitivity in patients with esophageal squamous cell carcinoma

Basic objectives2

Others

Basic objectives -Others

Prediction of chemoradiosensitivity

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1 year disease free survival

Key secondary outcomes

1 year local disease free survival, 3 year disease free survival, 3 year over all survival, pathological complete response


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

CDDP 70mg/m2 day1, day 29,5-FU 700mg/m2 day 1-4, day 29-32+radiation 60Gy or CDDP 75mg/m2 day1, day 29, 5-FU 1000mg/m2 day 1-4, day 29-32+radiation 50.4Gy. Salvage surgery for nonCR case

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Histologically proven squamous cell carcinoma of the thoracic esophagus 2) Clinical Stage IIa, IIb, III except T4 3) No previous history of chemotherapy nor radiotherapy 4) Above 20 years old and below 75 years old 5) An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 6)Written informed consent obtained before treatment and esophageal biopsy 7) An essentially normal clinical laboratory profile (white blood cell count or WBC, >=4000/mm3; platelet count or Plt, >=100,000/mm3; hemoglobin or Hb >=10g/dl; aspartate aminotransaminase or AST and alanine aminotransaminase or ALT, =<100IU/l; total serum bilirubin=<1.5mg/dl; creatinin or Cr, =<1.2; creatinine clearance or CCr, >=60ml/minute; and saturated arterial oxygen or SpO2, 95% >= ECG, no abnormal findings or no need for treatment

Key exclusion criteria

1) Severe complication (heart failure, renal failure, hepatic failure, uncontrollable diabetes melitus) 2) Active bacterial infection 3) Previous radiotherapy for the chest 4)Interstitial Pneumonitis or pulmonary fibrosis 5) Tumor extend to the cervical esophagus or cardia of the stomach 6) Synchronous or metachronous malignancy 7) Multiple and different histological types of cancer 8) Pregnant female 9) Mental disease 10) Collagen disease (PSS, dermatomiositis ) 11) Tumor diameter, 8cm >= 12) Virus infection (HBV, HCV, PTHA, HIV)

Target sample size

160


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yutaka Shimada MD

Organization

University of Toyama

Division name

Department of Surgery & Science

Zip code


Address

930-0194 Sugitani 2630, Toyama, Japan

TEL

076-434-7331

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yutaka Shimada MD

Organization

University of Toyama

Division name

Department of Surgery & Science

Zip code


Address

930-0194 Sugitani 2630, Toyama, Japan

TEL

076-434-7331

Homepage URL


Email

yshimada@med.u-toyama.ac.jp


Sponsor or person

Institute

University of Toyama

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Translational Research Informatics Center,
Foundation for Biomedical Research and Innovation

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

TRIEC0601

Org. issuing International ID_1

Translational Research Informatics Center,

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

富山大学病院(富山県)
愛知県立がんセンター(愛知県)
京都大学病院(京都府)
国立がんセンター中央病院(東京都)
国立がんセンター東病院(東京都)
近畿大学病院(大阪府)
群馬大学病院(群馬県)
鹿児島大学病院(鹿児島県)
川崎医科大学病院(岡山県)
九州がんセンター(福岡県)
琉球大学病院(沖縄県)
東京女子医大病院(東京都)
千葉大学病院(千葉県)
山形大学病院(山形県)
新潟大学病院(新潟県)
新潟がんセンター(新潟県)
大阪市立大学病院(大阪府)
国際福祉大学三田病院(東京都)
安佐市民病院(広島県)
岩手医科大学病院(岩手県)


Other administrative information

Date of disclosure of the study information

2007 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2006 Year 12 Month 26 Day

Date of IRB


Anticipated trial start date

2007 Year 02 Month 01 Day

Last follow-up date

2012 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2006 Year 08 Month 29 Day

Last modified on

2009 Year 09 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000579


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name